Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care
Jun 25, 2015 ·
6m 1s
![Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care](https://d3wo5wojvuv7l.cloudfront.net/t_square_limited_480/images.spreaker.com/original/42e5e18ddb21d203ac8e661da38f5929.jpg)
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action...
show more
Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?
show less
Information
Author | cancerGRACE |
Website | - |
Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company